#Zasocitinib logró una tasa PASI 100 >2,5 veces mayor que deucravacitinib en un ensayo fase 3 comparativo directo de #psoriasis, con seguridad consistente y dosis oral diaria única.
www.ipharmacenter.com/post/takeda-...
#noticias #farma #salud #pharma #healthcare #globalhealth #lifesciences
Takeda reports that its investigational oral therapy Zasocitinib achieved markedly stronger outcomes than deucravacitinib in a head-to-head Phase 3 trial in adults with moderate to severe plaque psori...
